LBA19 Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study

Publication | Open Access

DOI Full Paper Access

Citations

References

2023

Year

Luca Gianni, Chiun‐Sheng Huang, Daniel Egle, Begoña Bermejo, Claudio Zamagni, Marc Thill, A. Antón Torres, Giampaolo Bianchini, E. Sevillano Fernandez, Stefania Russo,

Annals of Oncology

Breast OncologyOncologyMedicinePathologyBreast CancerAnti-cancer AgentCancer TreatmentNeoadjuvant Taxane/carboplatinPharmacologyRadiation OncologyLba19 Event-free SurvivalNeotrip Michelangelo